

line 7, after "3'", insert --(SEQ ID NO:8)--;

line 12, after "3'", insert --(SEQ ID NO:9)--;

line 14, after "3'", insert --(SEQ ID NO:10)--.

Page 34, line 5, after "3'", insert --(SEQ ID NO:11)--;

line 8, after "3'", insert --(SEQ ID NO:12)--.

Page 35, line 5, after "3'", insert --(SEQ ID NO:13)--;

line 8, after "3'", insert --(SEQ ID NO:14)--.

Page 36, line 5, after "3'", insert --(SEQ ID NO:15)--;

line 7, after "3'", insert --(SEQ ID NO:16)--;

line 10, after "3' linker", insert --(SEQ ID NO:17)--;

line 12, after "3'", insert --(SEQ ID NO:18)--.

Sequence Listing

After Page 36, and before the claims, please insert the attached Sequence Listing.

IN THE CLAIMS:

Please amend claims 1, 5-7, and 9-13 as follows.

1. (Amended) A compound containing an antigen binding region which is bound to at least one prodrug-activating enzyme, where the antigen binding region is composed of a single polypeptide chain, and where the antigen binding region has a bivalent or a multivalent structure.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000

SAC
5.(Amended) A compound as claimed in claim 3, wherein the TAA is selected from the group consisting essentially of an N-CAM, PEM, EGF-R, Sialyl-Le^a, Sialyl-Le^X, TF β , GICA, GD₃, GD₂, TAG72, CA125, the 24-25 kDa glycoprotein defined by Mab L6, [or] and CEA[, preferably a CEA]

6. (Amended) A compound as claimed in claim 1, wherein the enzyme is selected from the group consisting essentially of a lactamase, [preferably a Bacillus cereus II β -lactamase] pyroglutamate aminopeptidase, D-aminopeptidase, oxidase, peroxidase, phosphatase, hydroxynitrile lyase, protease, esterase, carboxypeptidase [, preferably a carboxypeptidase G2 from Pseudomonas or] and glycosidase.

7. (Amended) A compound as claimed in claim 6, wherein the enzyme is a β -glucuronidase, [preferably a] which is selected from the group consisting of an E. coli β -glucuronidase, a Kobayasia nipponica β -glucuronidase, a Secale cereale β -glucuronidase [or] and a human β -glucuronidase.

9. (Amended) A compound as claimed in claim [1] 2, wherein [the] glycosylation covalently bonds the carbohydrates to the compound, and the glycosylation takes place either by means of chemical methods or by a selection of suitable expression systems.

SAC
10. (Amended) A compound as claimed in claim 1, which undergoes secretory expression in Saccharomyces cerevisiae or[, more advantageously,] in Hansenula polymorpha.

11. (Amended) A compound as claimed in claim 1, which is expressed in E. coli and is subsequently chemically glycosylated[, preferably galactosylated and/or mannosylated].

12. (Amended) A compound as claimed in claim [1] 30, wherein the sFv- β -lactamase fusion protein[, which] has undergone periplasmic expression in *E. coli*[.] and is chemically glycosylated[, preferably galactosylated and/or mannosylated].

13. (Amended) A compound as claimed in claim [1] 30, wherein the sFv- β -lactamase fusion protein undergoes secretory expression in *Saccharomyces cerevisiae* or *Hansenula polymorpha*.

Please add claims 27-33 as follows:

27. A compound as claimed in claim 6, wherein the lactamase enzyme is a *Bacillus cereus* II β -lactamase.

28. A compound as claimed in claim 6, wherein the carboxypeptidase enzyme is a carboxypeptidase G2 from *Pseudomonas*.

29. A compound as claimed in claim 10, which undergoes secretory expression in *Hansenula polymorpha*.

30. A compound as claimed in claim 1, wherein the antigen binding region and at least one prodrug-activating enzyme form an sFv- β -lactamase fusion protein.

31. A compound as claimed in claim 11, wherein the chemical glycosylation involves at least one of galactosylation or mannosylation.

32. A compound as claimed in claim 12, wherein the chemical glycosylation involves at least one of galactosylation or mannosylation.